CN1511526A - Rifaximin ointment - Google Patents
Rifaximin ointment Download PDFInfo
- Publication number
- CN1511526A CN1511526A CNA021591318A CN02159131A CN1511526A CN 1511526 A CN1511526 A CN 1511526A CN A021591318 A CNA021591318 A CN A021591318A CN 02159131 A CN02159131 A CN 02159131A CN 1511526 A CN1511526 A CN 1511526A
- Authority
- CN
- China
- Prior art keywords
- rifaximin
- ointment
- gross weight
- accounts
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The Rifaximin ointment consists of emulsifier matrix, transdermal promoter, humectant and Rifaximin as the active component. The preparation process includes homogeneous mixing of Rifaximin as the active component and emulsifier matrix in the formula amount, the mixing with transdermal promoter and humectant to form orange ointment and final packing. The present invention has wide antibacterial spectrum, miraculous effect in treating conjunctivitis, keratitis, trachoma and other eye diseases and various infectious dermatitis, quick and lasting effect and high curative rate.
Description
Technical field
The present invention relates to a kind of externally-applied ointment medicament, particularly relate to a kind of medicine ointment that is used for the treatment of ophthalmic inflammations such as trachoma, conjunctivitis, keratitis and infectious skin disease.
Background technology
Rifaximin (Rifamixin) belongs to a kind of antibiotic, is a kind of derivant of rifamycin, and its chemistry is by name: 4-deoxidation-4 '-picoline [1 ', 2 '-1,2] imidazo [5,4-C] Rifamycin Sodium also.Rifaximin is dissolved in ethanol, ethyl acetate, chloroform and toluene, but water insoluble.The has a broad antifungal spectrum of rifaximin, to Salmonella, escherichia coli, Shigella, yersinia enterocolitica, the coccus in the aurococcus in the Gram-positive aerobe, staphylococcus epidermidis and streptococcus faecalis, the irregular oxygen bacterium of Gram-negative, Bacteroides in the gram-negative anaerobic bacteria all has high activity, and toxic and side effects is extremely low, so be widely used in treating the acute and chronic intestinal infection that causes by gram positive bacteria and gram negative bacteria in recent years, also be used as the ancillary drug for the treatment of vascular hypertension simultaneously.For example, Chinese patent application prospectus CN1214244 (application number 98106920) discloses the purposes of a kind of rifaximin in the diarrhoea that treatment is caused by cryptosporidiosis.
Summary of the invention
Technical problem to be solved by this invention is, the new purposes of exploitation rifaximin provides a kind of Rifaximin ointment that is used for the treatment of ophthalmic inflammation such as trachoma, conjunctivitis, keratitis and infectious skin disease.
In order to solve the problems of the technologies described above, the technical solution used in the present invention is: Rifaximin ointment of the present invention comprises: emulsion-type substrate, transdermal enhancer, wetting agent and active component rifaximin.
Rifaximin ointment of the present invention can also comprise: pharmaceutically acceptable other adjuvant.
The prescription of Rifaximin ointment of the present invention is:
A. emulsion-type substrate: form by O/W emulsifying agent, water and oil phase, account for the 80-90% of ointment formulation gross weight;
Wherein: the O/W emulsifying agent is selected from Tweens, sodium lauryl sulphate, ethanolamine, triethanolamine and stearic acid mixture, accounts for the 10-20% of emulsion-type substrate gross weight;
Water is selected liquid paraffin, water and alcoholic acid mixture for use, and three's part by weight is 1: 7: 2, accounts for the 60-70% of emulsion-type substrate gross weight;
Oil phase is selected white vaseline and stearic mixture for use, and the two part by weight is 2: 3, accounts for the 15-30% of emulsion-type substrate gross weight;
D. transdermal enhancer is selected from azone, arsenic is coughed up ketone, polyalcohols, saturated or unsaturated fatty acid and ester, sulfoxide, amide, lactams or other pharmaceutically acceptable nonionic surfactant, accounts for the 1-5% of ointment formulation gross weight;
E. wetting agent is a glycerol, accounts for the 3-10% of ointment formulation gross weight;
D. active component is a rifaximin, accounts for the 1-5% of ointment gross weight;
The preparation method of Rifaximin ointment of the present invention is: according to formula ratio, at first with active component rifaximin and the abundant mix homogeneously of emulsion-type substrate, add transdermal enhancer, wetting agent and abundant mix homogeneously then successively, form the Chinese red mastic, last packing promptly.
The beneficial effect of Rifaximin ointment of the present invention is: has a broad antifungal spectrum, ocular disease such as treatment conjunctivitis, keratitis, trachoma and various infectious skin disease all there are special effect, and rapid-action, effect is lasting, cure rate is high, is a kind of new purposes of rifaximin.
The specific embodiment
Below in conjunction with the specific embodiment Rifaximin ointment of the present invention is described in further detail:
Embodiment 1
The prescription of present embodiment is:
A. emulsion-type substrate: form by O/W emulsifying agent, water and oil phase, account for 84% of ointment formulation gross weight;
Wherein: the O/W emulsifying agent is a sodium lauryl sulphate, accounts for 10% of emulsion-type substrate gross weight;
Water is liquid paraffin, water and alcoholic acid mixture, and three's part by weight is 1: 7: 2, accounts for 70% of emulsion-type substrate gross weight;
Oil phase is white vaseline and stearic mixture, and the two part by weight is 2: 3, accounts for 20% of emulsion-type substrate gross weight;
B. the transdermal enhancer azone accounts for 4% of ointment formulation gross weight;
C. wetting agent glycerol accounts for 8% of ointment formulation gross weight;
D. the active component rifaximin accounts for 4% of ointment gross weight.
The preparation method of present embodiment is: according to formula ratio, at first with active component rifaximin and the abundant mix homogeneously of emulsion-type substrate, add transdermal enhancer azone, wetting agent glycerol and abundant mix homogeneously then successively, form the Chinese red mastic, last packing promptly.
Embodiment 2
The prescription of present embodiment is:
A. emulsion-type substrate: form by O/W emulsifying agent, water and oil phase, account for 80% of ointment formulation gross weight;
Wherein: the O/W emulsifying agent is an ethanolamine, accounts for 15% of emulsion-type substrate gross weight;
Water is selected liquid paraffin, water and alcoholic acid mixture for use, and three's part by weight is 1: 7: 2, accounts for 60% of emulsion-type substrate gross weight;
Oil phase is selected white vaseline and stearic mixture for use, and the two part by weight is 2: 3, accounts for 25% of emulsion-type substrate gross weight;
B. transdermal enhancer arsenic is coughed up ketone, accounts for 5% of ointment formulation gross weight;
C. wetting agent glycerol accounts for 10% of ointment formulation gross weight;
D. the active component rifaximin accounts for 5% of ointment gross weight.
The preparation method of present embodiment is: according to formula ratio, at first with active component rifaximin and the abundant mix homogeneously of emulsion-type substrate, add transdermal enhancer arsenic then successively and cough up ketone, wetting agent glycerol and abundant mix homogeneously, form the Chinese red mastic, last packing promptly.
Embodiment 3
The prescription of present embodiment is:
A. emulsion-type substrate: form by O/W emulsifying agent, water and oil phase, account for 88% of ointment formulation gross weight;
Wherein: the O/W emulsifying agent is triethanolamine and stearic acid mixture, and the two part by weight is 3: 7, accounts for 13% of emulsion-type substrate gross weight;
Water is selected liquid paraffin, water and alcoholic acid mixture for use, and three's part by weight is 1: 7: 2, accounts for 68% of emulsion-type substrate gross weight;
Oil phase is selected white vaseline and stearic mixture for use, and the two part by weight is 2: 3; Account for 19% of emulsion-type substrate gross weight;
B. the transdermal enhancer polyalcohols accounts for 3% of ointment formulation gross weight;
C. wetting agent glycerol accounts for 7% of ointment formulation gross weight.
D. the active component rifaximin accounts for 2% of ointment gross weight.
The preparation method of present embodiment is: according to formula ratio, at first with active component rifaximin and the abundant mix homogeneously of emulsion-type substrate, add transdermal enhancer polyalcohols, wetting agent glycerol and abundant mix homogeneously then successively, form the Chinese red mastic, last packing promptly.
Claims (3)
1. Rifaximin ointment, comprising: emulsion-type substrate, transdermal enhancer and wetting agent is characterized in that; Also comprise the active component rifaximin.
2. Rifaximin ointment according to claim 1 is characterized in that: its prescription is:
A. emulsion-type substrate: form by O/W emulsifying agent, water and oil phase, account for the 80-90% of ointment formulation gross weight;
Wherein: the O/W emulsifying agent is selected from Tweens, sodium lauryl sulphate, ethanolamine, triethanolamine and stearic acid mixture, accounts for the 10-20% of emulsion-type substrate gross weight;
Water is selected liquid paraffin, water and alcoholic acid mixture for use, and three's part by weight is 1: 7: 2, accounts for the 60-70% of emulsion-type substrate gross weight;
Oil phase is selected white vaseline and stearic mixture for use, and the two part by weight is 2: 3, accounts for the 15-30% of emulsion-type substrate gross weight;
B. transdermal enhancer is selected from azone, arsenic is coughed up ketone, polyalcohols, saturated or unsaturated fatty acid and ester, sulfoxide, amide, lactams or other pharmaceutically acceptable nonionic surfactant, accounts for the 1-5% of ointment formulation gross weight;
C. wetting agent is a glycerol, accounts for the 3-10% of ointment formulation gross weight;
D. active component is a rifaximin, accounts for the 1-5% of ointment gross weight;
3. the preparation method of a Rifaximin ointment, it is characterized in that:,, add transdermal enhancer, wetting agent and abundant mix homogeneously then successively at first with active component rifaximin and the abundant mix homogeneously of emulsion-type substrate according to formula ratio, form the Chinese red mastic, last packing promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021591318A CN1511526A (en) | 2002-12-30 | 2002-12-30 | Rifaximin ointment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021591318A CN1511526A (en) | 2002-12-30 | 2002-12-30 | Rifaximin ointment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1511526A true CN1511526A (en) | 2004-07-14 |
Family
ID=34237325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021591318A Pending CN1511526A (en) | 2002-12-30 | 2002-12-30 | Rifaximin ointment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1511526A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018534358A (en) * | 2015-10-08 | 2018-11-22 | エーエムディー セラピューティックス エルエルシー | Treatment of skin disorders by topical administration of VEGF inhibitors |
| JP2022137176A (en) * | 2014-07-21 | 2022-09-21 | エーエムディー セラピューティックス エルエルシー | Ophthalmic composition of rifamycin, and use of the same |
-
2002
- 2002-12-30 CN CNA021591318A patent/CN1511526A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022137176A (en) * | 2014-07-21 | 2022-09-21 | エーエムディー セラピューティックス エルエルシー | Ophthalmic composition of rifamycin, and use of the same |
| US11850213B2 (en) | 2014-07-21 | 2023-12-26 | Amd Therapeutics Llc | Ophthalmic compositions of rifamycins and uses thereof |
| JP2018534358A (en) * | 2015-10-08 | 2018-11-22 | エーエムディー セラピューティックス エルエルシー | Treatment of skin disorders by topical administration of VEGF inhibitors |
| JP7187310B2 (en) | 2015-10-08 | 2022-12-12 | エーエムディー セラピューティックス エルエルシー | Treatment of skin disorders by topical administration of VEGF inhibitors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101538280B1 (en) | Ophthalmic compositions comprising povidone-iodine | |
| CN1649603A (en) | Aqueous compositions containing metronidazole | |
| CN1897917A (en) | Suspension of loteprednol etabonate and tobramycin for topical ophthalmic use | |
| CN1193668C (en) | Application of compound pesticide in preventing and treating rice sheath blight disease | |
| CN1511526A (en) | Rifaximin ointment | |
| CN1729778A (en) | Sterilizing agent, preparation method and use thereof | |
| WO2003077830A3 (en) | 9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives | |
| CN1843358A (en) | Ketoconazole eye drops and fabricating method thereof | |
| CN1569366A (en) | Nano-silver aqueous solution preparation and its preparation method, use and using method | |
| CN104470502B (en) | Anti-bacterial drug composition | |
| CN1205942C (en) | Archimycin gel for eye application | |
| EP1932525B1 (en) | Skin-care preparations containing mupirocin and betamethasone dipropionate | |
| CN1378782A (en) | Agricultural bactericide series prepared from raw powder of hymexazol as main raw material | |
| AU642464B2 (en) | Water soluble salts of purpuromycin and pharmaceutical formulations thereof | |
| CN1742718A (en) | Method for preparing rifamicina injecta | |
| CN1098075C (en) | Broad-spectrum antibacterial medicine and its exterior application method | |
| CN1895253A (en) | Lomesaline hydrochloride eye drops and preparation thereof | |
| CN117618342B (en) | Preparation method of amikacin sulfate injection | |
| CN1879633A (en) | Compound sulfamethoxazole injection for animal, its preparation method and use | |
| CN1244320C (en) | Nose spray agent | |
| CN1203862C (en) | Compound glucose injection with clindamycin and metronidazole | |
| CN1562031A (en) | Gatifloxacin gels and its preparing method | |
| CN1131039C (en) | Kelamycin injection and its preparing process | |
| CN1167421C (en) | Medicine composition containing pyrroloquinolinequinone for treating saturnism | |
| CN1861063A (en) | Ophthalmic gel contg. neo-decanoy acetaldehyde sodium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |